Lonza extends partnership with Pharmacyclics

14-Jan-2014 - Switzerland

Lonza announced it has established an agreement with Pharmacyclics, Inc. to  support the commercial and clinical production of its first-in-class oral oncology drug, IMBRUVICA™ (Ibrutinib).  This agreement follows a multi-year partnership, including the development and clinical manufacturing, which was utilized for Pharmacyclics’ NDA submission and now first FDA approval of their lead product for oncology treatment.  Under the long term agreement, Lonza will continue to support the production of commercial and clinical material.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!